Cytokinetics, Incorporated

Cytokinetics develops muscle activators and inhibitors as potential treatments for debilitating diseases. Its drug candidates include omecamtiv mecarbil (Phase III trial), CK-136 (Phase I trial), CK-586 (Phase I trial), and aficamten (Phase III trial). The company focuses on small molecule drug candidates that impact muscle function and contractility. It has a strategic alliance with Ji Xing Pharmaceuticals Limited. Cytokinetics is headquartered in South San Francisco, California.

Overview

Sector
Biotechnology
Target Price
0.0 USD
Current Price
33.2 USD
Potential
-100%

Strengths

  • No significant strengths identified based on the analyzed metrics.

Weaknesses

  • With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
  • Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
  • The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
  • The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
  • EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

IndicatorValue
PER100.0
EV/EBITDA100.0
Price/Free Cash Flow'100.0
ROIC-%
Net Debt/EBITDA100.0
    Cytokinetics, Incorporated | Stock Comparator